

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse Matrilin-3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 50% cross-reactivity with recombinant human Matrilin-3 is observed and 5% cross-reactivity with recombinant mouse (rm) Matrilin-2 and rmMatrilin-4 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse Matrilin-3 Ala35-Arg481 Accession # AAH71224
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Mouse Matrilin-3 (Catalog # 3357-MN)

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Matrilin-3 is a 50-60 kDa extracellular matrix protein that belongs to the superfamily of von Willebrand factor A (VWA) containing proteins. It is primarily expressed in cartilage and functions as a bridging component between proteins of the collagenous matrix (1-3). The mouse Matrilin-3 cDNA encodes a 481 amino acid (aa) precursor with a 27 aa signal sequence, an N-terminal VWA domain, four tandem EGF-like repeats, and a C-terminal coiled-coil domain (4). The Matrilins differ in the number of VWA domains (one or two) and EGF-like repeats (one, three, four, or ten) they contain. Mouse Matrilin-3 shares 82% aa sequence identity with human Matrilin-3. Within the first VWA domain, mouse Matrilin-3 shares approximately 51% aa sequence identity with mouse Matrilin-1, -2, and -4. The coiled-coil domain of Matrilin-3 mediates disulfide-linked homo-oligomerization, with tetramer formation being the most dominant (5-7). It can also assemble into hetero-oligomers with Matrilin-1 (5-7). Matrilin-3 is more plentiful than Matrilin-1 in the proliferative zone of the growth plate, whereas the reverse is true in the maturation zone (5). Matrilin-3 interacts directly with Collagen IX and COMP (8, 9). In the absence of Collagen IX, the expression of Matrilin-3 is unchanged, although it is retained inside chondrocytes and is not incorporated into the matrix (9). Intracellular retention of Matrilin-3 also occurs with particular point mutations in the VWA domain that results in multiple epiphyseal dysplasia (11-13). In contrast, a point mutation in the first EGF-like repeat which has been linked to hand osteoarthritis does not prevent Matrilin-3 secretion (13). Matrilin-3 knockout mice do not display any obvious abnormalities, suggesting that other molecules may compensate for the lack of Matrilin-3 (10).

References:

1. Wagener, R. *et al.* (2005) FEBS Lett. **579**:3323.
2. Deak, F. *et al.* (1999) Matrix Biol. **18**:55.
3. Whittaker, C.A. and R.O. Hynes (2002) Mol. Biol. Cell **13**:3369.
4. Wagener, R. *et al.* (1997) FEBS Lett. **413**:129.
5. Zhang, Y. and Q. Chen (2000) J. Biol. Chem. **275**:32628.
6. Klatt, A.R. *et al.* (2000) J. Biol. Chem. **275**:3999.
7. Frank, S. *et al.* (2002) J. Biol. Chem. **277**:19071.
8. Mann, H.H. *et al.* (2004) J. Biol. Chem. **279**:25294.
9. Budde, B. *et al.* (2005) Mol. Cell. Biol. **25**:10465.
10. Ko, Y. *et al.* (2004) Mol. Cell. Biol. **24**:1691.
11. Jackson, G.C. *et al.* (2004) J. Med. Genet. **41**:52.
12. Cotterill, S.L. *et al.* (2005) Hum. Mutat. **26**:557.
13. Otten, C. *et al.* (2005) J. Med. Genet. **42**:774.